BIO-key International (BKYI) Q1 2024 earnings summary

Executive summary

• Q1 2024 revenue reached $2.2 million, flat year-over-year but up 19.5% sequentially, driven by expanded biometric deployments for a key financial services client in South Africa.

• Net loss narrowed to $0.5 million from $1.7 million in Q1 2023, reflecting improved gross margin and reduced operating expenses.

• Operating loss was reduced by over 70% year-over-year to $509,000 in Q1 2024, aided by cost reductions and higher-margin revenue.

• Operating cash flow turned positive at $0.3 million, compared to a $1.9 million outflow in Q1 2023, benefiting from a $1.5 million license extension payment.

• The company launched Passkey:YOU, a passwordless, biometric authentication solution targeting shared workstation environments.

Financial highlights

• License fee revenue rose 24% year-over-year, offsetting declines in services and hardware revenue.

• Gross profit increased to $1.9 million from $0.9 million in Q1 2023; gross margin improved to 86% from 40% (or 62% excluding prior year hardware reserve expense).

• Operating expenses decreased by 9% year-over-year, including reductions in SG&A and R&D.

• Cash and equivalents at quarter-end were $690,000, with total current assets of $2.3 million.

• Net cash provided by operations was $297,000, a turnaround from a $1.93 million outflow in Q1 2023.

Outlook and guidance

• Management expects continued revenue growth, ARR expansion, and progress toward profitability and positive cash flow in coming quarters.

• Several large projects in healthcare, financial services, and defense are in the proposal or proof-of-concept stage.

• Ongoing efforts to monetize $3.6 million in reserved inventory and explore new markets for delayed Nigeria projects.